On November 9, 2018, MediRätt announced that the company had called upon a second tranche of convertibles under the agreement on financing through issuance of convertibles entered into with European Select Growth Opportunities Fund (the "Investor"). MediRätt also informed that the company had decided to, at no consideration, issue 430,851 warrants TO6 to the Investor and 426,692 warrants to iZafe AB (formerly Sensec Personlig Säkerhet AB, currently under name change) with the right and obligation to transfer its warrants at no consideration to the shareholders in MediRätt pro rata in proportion to the number of shares in MediRätt they hold at the date five trading days after the date of registration of the issue resolution at the Swedish Companies Registration Office.
The shareholders of MediRätt AB, 556762-3391, (the "Company") are hereby invited to an Extraordinary General Meeting on Tuesday, 18 December 2018 at 14.00, at Priority, Skeppsbron 24, Stockholm, Sweden.
On May 21, 2018, MediRätt and European Select Growth Opportunities Fund (the "Investor") signed an agreement under which MediRätt may issue convertible bonds in several tranches for a total maximum amount of SEK 50 million over 18 months. A first tranche of SEK 2.5 million has been issued on June 13, under which all the convertibles have been converted into shares as of today, strengthening the company's equity.
Today, MediRätt's subsidiary signed an agreement with Borlänge municipality after winning a direct procurement for courses in security training. Under the agreement, Sensec will train Borlänge municipality staff on 10 to 15 occasions in three different areas: threats and violence in the workplace, ongoing deadly violence, and emergency preparedness.
In conjunction with MediRätt's Q3 report, Erik Penser Bank today published a follow-up analysis of the company. Against a background of higher than expected sales for Q3, the bank has revised upwards its EBIT estimate by SEK 1.8 million for 2018.
THIRD QUARTER IN BRIEF
2,704 SEK 000s (0 SEK 000s)
PROFIT AFTER TAX:
-2,101 SEK 000s (-1,100 SEK 000s)
PROFIT PER SHARE BEFORE DILLUTION:
-0.2 SEK (-0.1 SEK)
NUMBER OF SHARES AS AT 30 JUNE:
Today, MediRätt has signed a pilot project agreement for Dosell with Uppsala municipality. The trial will be conducted for a period of six months with the option of an extension. If the test is successful, Uppsala municipality may decide to purchase Dosell through a public procurement process.
The process to obtain CE marking for Dosell as a MDD Class 1 medtech product continues as planned. MediRätt is expecting that the process can be completed during week 48.
Yesterday, Erik Penser Bank published an analysis of MediRätt. The share was valued at approximately SEK 22 according to the bank's "base" scenario, which indicates high potential at high risk, according to the bank.
In the summer, MediRätt began a co-operation with Erik Penser Bank regarding independent analysis reports on the company. Following delays, the first analysis is expected to be published next week.
Pressmeddelanden och rapporter via E-post.